TP53 and neoplasm: Conversely, growth of ENO1-deficient HCT-116 p53−/− tumors was inhibited by doxorubicin but not A-1331852; adding A-1331852 to doxorubicin did not further inhibit tumor growth compared to doxorubicin alone (Fig. 6E).